Case and Research Letters
The safety of dupilumab in clinical practice: 52 weeks of experience at 5 referral hospitals in Andalusia
Análisis de seguridad de dupilumab en práctica clínica real. Experiencia a 52 semanas de cinco centros de referencia en Andalucía
Leído
6396
Vecesse ha leído el artículo
1804
Total PDF
4592
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 87 | 2 | 89 |
| 2025 5 | 249 | 35 | 284 |
| 2025 4 | 189 | 22 | 211 |
| 2025 3 | 163 | 20 | 183 |
| 2025 2 | 161 | 42 | 203 |
| 2025 1 | 129 | 32 | 161 |
| 2024 12 | 112 | 27 | 139 |
| 2024 11 | 141 | 58 | 199 |
| 2024 10 | 100 | 40 | 140 |
| 2024 9 | 115 | 21 | 136 |
| 2024 8 | 141 | 42 | 183 |
| 2024 7 | 112 | 29 | 141 |
| 2024 6 | 116 | 24 | 140 |
| 2024 5 | 83 | 35 | 118 |
| 2024 4 | 76 | 25 | 101 |
| 2024 3 | 61 | 28 | 89 |
| 2024 2 | 53 | 35 | 88 |
| 2024 1 | 87 | 33 | 120 |
| 2023 12 | 101 | 19 | 120 |
| 2023 11 | 88 | 28 | 116 |
| 2023 10 | 95 | 21 | 116 |
| 2023 9 | 86 | 28 | 114 |
| 2023 8 | 58 | 13 | 71 |
| 2023 7 | 74 | 32 | 106 |
| 2023 6 | 87 | 23 | 110 |
| 2023 5 | 90 | 28 | 118 |
| 2023 4 | 63 | 20 | 83 |
| 2023 3 | 95 | 25 | 120 |
| 2023 2 | 79 | 27 | 106 |
| 2022 1 | 59 | 28 | 87 |
| 2022 12 | 74 | 39 | 113 |
| 2022 11 | 30 | 31 | 61 |
| 2022 10 | 42 | 24 | 66 |
| 2022 9 | 31 | 43 | 74 |
| 2022 8 | 37 | 29 | 66 |
| 2022 7 | 58 | 38 | 96 |
| 2022 6 | 34 | 22 | 56 |
| 2022 5 | 49 | 39 | 88 |
| 2022 4 | 76 | 24 | 100 |
| 2022 3 | 99 | 46 | 145 |
| 2022 2 | 66 | 30 | 96 |
| 2021 1 | 78 | 46 | 124 |
| 2021 12 | 42 | 33 | 75 |
| 2021 11 | 48 | 40 | 88 |
| 2021 10 | 47 | 60 | 107 |
| 2021 9 | 44 | 44 | 88 |
| 2021 8 | 38 | 33 | 71 |
| 2021 7 | 44 | 29 | 73 |
| 2021 6 | 46 | 27 | 73 |
| 2021 5 | 37 | 35 | 72 |
| 2021 4 | 58 | 76 | 134 |
| 2021 3 | 70 | 35 | 105 |
| 2021 2 | 49 | 34 | 83 |
| 2020 1 | 80 | 19 | 99 |
| 2020 12 | 43 | 32 | 75 |
| 2020 11 | 71 | 27 | 98 |
| 2020 10 | 32 | 21 | 53 |
| 2020 9 | 19 | 6 | 25 |
Mostrar todo
